Added FDA approval for Vertex' Trikafta

Shares of US drugmaker Vertex Pharmaceuticals (Nasdaq: VRTX) closed down 2.6% at $323.30 yesterday, despite the firm announcing that the US Food and Drug Administration (FDA) has approved the expanded use of Trikafta (elexacaftor/tezacaftor/ivacaftor and ivacaftor).

Trikafta, also marked under the trade name Kaftrio, is by far the biggest selling product for Vertex, generating global revenues of $7.69 billion in 2022.

Trikafta’s indication now includes children with cystic fibrosis (CF) ages two through five years who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene or a mutation in the CFTR gene that is responsive to Trikafta based on in vitro data.